Hyperlipoproteinaemia(a) - apheresis and emerging therapies.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
niacin 3 endocrinologydiseasesdrugs
Alirocumab 3 endocrinologydiseasesdrugs
Evolocumab 2 endocrinologydiseasesdrugs
atorvastatin 2 endocrinologydiseasesdrugs
ezetimibe 1 endocrinologydiseasesdrugs

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Alirocumab 9712 50–60% and in some trials a lowering of Lp(a) [[45]–[48]] was seen as well (Evolocumab 25.5% [[46]], Alirocumab 30.2% [[45]]).A pooled analysis [[48]] of three phase-2 Alirocumab trials specifically analysed the
Alirocumab 9780 well (Evolocumab 25.5% [[46]], Alirocumab 30.2% [[45]]).A pooled analysis [[48]] of three phase-2 Alirocumab trials specifically analysed the effect on Lp(a). Baseline levels between 2 and 181 mg/dl were parted
Alirocumab 10773 [[51]].The results of the endpoint trials are expected in early 2017 (Evolocumab [[52]]) and in 2018 ( Alirocumab [[53]]). Whether lowering Lp(a) by PCSK9-inhibitors contributes to the expected beneficial cardiovascular
Evolocumab 9687 reduction is about 50–60% and in some trials a lowering of Lp(a) [[45]–[48]] was seen as well ( Evolocumab 25.5% [[46]], Alirocumab 30.2% [[45]]).A pooled analysis [[48]] of three phase-2 Alirocumab trials
Evolocumab 10741 frequent injection site reactions [[51]].The results of the endpoint trials are expected in early 2017 ( Evolocumab [[52]]) and in 2018 (Alirocumab [[53]]). Whether lowering Lp(a) by PCSK9-inhibitors contributes to the
atorvastatin 5842 than patients with low Lp(a) and high levels of LDL-c [[29]]. One prospective open-label trial used atorvastatin plus the a selective Lp(a) lowering apheresis system (treatment group) and atorvastatin alone (control
atorvastatin 5931 trial used atorvastatin plus the a selective Lp(a) lowering apheresis system (treatment group) and atorvastatin alone (control group). After 18 months a small but significant regression of coronary atherosclerosis
ezetimibe 3650 increase of Lp(a) by statins [[12]], but mostly Lp(a) is not affected by statins [[10], [13], [14]] nor by ezetimibe [[15]]. Nicotinic acid (niacin) reduces Lp(a) besides positive effects on LDL-c, high density lipoprotein-cholesterol
niacin 3684 mostly Lp(a) is not affected by statins [[10], [13], [14]] nor by ezetimibe [[15]]. Nicotinic acid ( niacin ) reduces Lp(a) besides positive effects on LDL-c, high density lipoprotein-cholesterol (HDL-c), and
niacin 4360 confirmed in cohorts treated in line with current options and guidelines. In the EAS consensus paper niacin is recommended to reduce high levels of Lp(a) [[10]]. Since 2013 niacin is not available in Europe.
niacin 4432 In the EAS consensus paper niacin is recommended to reduce high levels of Lp(a) [[10]]. Since 2013 niacin is not available in Europe. In summary, no established drug treatment option to reduce Lp(a) is available
Select Disease Character Offset Disease Term Instance

You must be authorized to submit a review.